



Emerging growth company “

1

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    "

In this report, "Array BioPharma," "Array," "we," "us" and "our" refer to Array BioPharma Inc., unless the context otherwise provides.

Item 7.01 Regulation FD Disclosure.

On June 23, 2018, Array BioPharma Inc. issued a press release announcing additional results of encorafenib, binimetinib and cetuximab in patients with BRAF-mutant colorectal cancer that were presented at the ESMO 20<sup>th</sup> World Congress on Gastrointestinal Cancer. A copy of the press release is included as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	<u>Press release dated June 23, 2018.</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 25, 2018 Array BioPharma Inc.

By: /s/ JASON HADDOCK  
Jason Haddock  
Chief Financial Officer

